Viridian Therapeutics, Inc. VRDN Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Viridian Therapeutics, Inc. (VRDN) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $612K in Q1 2026.
- How has Viridian Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Viridian Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 120.1% year-over-year, from $278K to $612K.
- What is the long-term trend for Viridian Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -26.3% compound annual growth rate (CAGR), from $163K to $48K.